Incyte vs. Sun Pharma: JAK Inhibitor Patent Case Dismissed After 401 Days
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Incyte Corporation v. Sun Pharmaceutical Industries, Inc. |
| Case Number | 2:24-cv-06944 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | June 2024 – July 2025 401 days |
| Outcome | Dismissed with Prejudice |
| Patents at Issue | |
| Accused Products | Sun Pharma’s Generic Jakafi® (ruxolitinib) |
Case Overview
The Parties
⚖️ Plaintiff
Biopharmaceutical company focused on oncology and inflammation, developer of Jakafi® (ruxolitinib).
🛡️ Defendant
Global specialty generic pharmaceutical manufacturer with a strong presence in ANDA litigation.
Patents at Issue
This case centered on **U.S. Patent No. 9,662,335 B2**, covering technology associated with Incyte’s flagship oncology product, **Jakafi® (ruxolitinib)**.
- • US 9,662,335 B2 — Formulations or methods associated with ruxolitinib
Developing a related pharmaceutical product?
Check if your drug formulation or method might infringe this or related patents.
Outcome & Legal Analysis
Outcome
The case concluded via **joint stipulation of dismissal with prejudice** under Fed. R. Civ. P. 41(a)(1)(A)(ii), with each party bearing its own attorneys’ fees and costs. No court ruling on validity or infringement was issued, and no damages award was made.
Key Legal Issues
The case was a classic **Hatch-Waxman ANDA-style infringement dispute**, focusing on Sun Pharma’s efforts to market a generic version of Jakafi®. The dismissal means no judicial precedent was set on the validity or scope of U.S. Patent No. 9,662,335 B2.
Filing a pharmaceutical patent?
Learn from this case. Use AI to draft stronger claims that can withstand litigation.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights the complexities of IP risks in the pharmaceutical sector. Choose your next step:
📋 Understand This Case’s Impact
Learn about the strategic signals and implications from this litigation.
- View Incyte’s broader JAK inhibitor patent portfolio
- Analyze ANDA litigation trends in pharma
- Understand the impact of stipulated dismissals
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
JAK1/JAK2 Inhibitors, Ruxolitinib Formulations
1 Patent at Issue
But part of broader Incyte portfolio
No Precedent Set
Patent validity remains unchallenged
✅ Key Takeaways
For Patent Attorneys & Litigators
Stipulated dismissals with prejudice can strategically resolve disputes without creating adverse precedent on patent validity.
Search related case law →New Jersey is a strategically important venue for Hatch-Waxman litigation; venue selection matters.
Explore precedents →For R&D Teams
Thorough FTO analyses, covering full patent families, are crucial before developing generic pharmaceutical products.
Start FTO analysis for my product →Early engagement in settlement discussions can avoid protracted and costly litigation for both branded and generic pharma.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.